纤溶酶原激活物抑制剂1 (PAI - 1)是一种单链糖蛋白，起抑制纤溶活性的作用。
Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
结论：益气通络丹的疗效机制与抑制脂质过氧化、保护内皮依赖性松弛因子和调节纤溶活性有关。
Conclusion: the protective mechanisms of YQTLP were related to inhibit lipid peroxidation, protect endothelium-derived relaxing factor and adjust the fibrinolytic activities.
目的观察罗格列酮对2型糖尿病患者血脂水平和血浆纤溶酶原激活物抑制剂1 (PAI - 1)活性的影响。
Objective To investigate the influence of rosiglitazone on blood lipids and plasma PAI-1 activity in type 2 diabetic patients.
目的：建立重组TFPI-2抑制纤溶酶活性的测定方法。
Objective: To establish a assay for plasmin inhibition with the recombinant TFPI-2.
PMSF和盐酸苯甲醚能抑制其纤溶活性，而EDTA和EGTA不能抑制，表明该酶是一种丝氨酸蛋白酶。
PMSF completely inhibited the fibrinolytic activity, but EDTA and EGTA exerted little effect on it. These results demonstrate that DFE is a serine protease.
目的：探讨纤溶酶原激活物抑制物-1 (PAI - 1)活性变化和其基因多态性对脑梗死及其再梗死发病的关系。
To investigate the changes of plasma PAI 1 activity and its gene polymorphism in cerebral infarction.
目的：探讨纤溶酶原激活物抑制物-1 (PAI - 1)活性变化和其基因多态性对脑梗死及其再梗死发病的关系。
To investigate the changes of plasma PAI 1 activity and its gene polymorphism in cerebral infarction.
应用推荐